Antibody-drug conjugates (ADCs) have become the cornerstone of effective therapeutics in solid and hematological malignancies by harnessing potent cytotoxic payloads with targeted tumoricidal delivery. Since the monumental shift occurred with HER2-targeted ADCs, the discovery of the TROP2 antigen has revolutionized the landscape of ADC development. Moving beyond the traditional ADC design, multiple novel ADCs have successfully shaped and improved survival outcomes in patients with various tumor histologies. Here we review and contrast the clinical impact of the well-known TROP2 ADCs currently in clinical use. We also shed light on upcoming investigational TROP2 ADCs showing promise with novel ADC platforms.

中文翻译：

---

在实体瘤中利用 TROP2 抗体药物偶联物

抗体药物偶联物 (ADC) 通过利用有效的细胞毒性有效负载进行靶向杀肿瘤治疗，已成为实体瘤和血液恶性肿瘤有效治疗的基石。自从 HER2 靶向 ADC 发生巨大转变以来，TROP2 抗原的发现彻底改变了 ADC 开发的格局。超越传统的 ADC 设计，多种新型 ADC 已成功塑造和改善具有各种肿瘤组织学的患者的生存结果。在此，我们回顾并对比目前临床使用的知名 TROP2 ADC 的临床影响。我们还介绍了即将推出的研究性 TROP2 ADC，它们在新颖的 ADC 平台上表现出了良好的前景。